SPA and Novo Nordisk to reach returned stock issues.

Published: 2006-04-14 06:58:00

Updated: 2006-04-14 06:58:00

The Seoul Pharmaceutical Association (SPA) and Novo Nordisk have confronted each other over the issue of idle returned stocks, and finally the SPA ended with favorable outcomes.

The SPA said in the negotiation with Novo Nordisk "Novo Nordisk has fully accepted all terms and conditions for the...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK